Hikma inks licensing deal with Orion for Easyhaler

Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland, for its new Easyhaler combination product, a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease.

Under the terms of the agreement, Hikma has the exclusive rights to register, distribute, market and sell the product in all of its MENA markets, leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.

At 9:28am: (LON:HIK) Hikma Pharmaceuticals PLC share price was +14.5p at 1951.5p

Story provided by StockMarketWire.com